ELI LILLY & Co

LLY Healthcare & Pharma 3/10 Low Risk
3/10

ELI LILLY & Co has $19.1B in total long-term debt with $8.3B in scheduled maturities. Approximately $781M (9% of maturities) is due within the next twelve months. Overall, LLY carries low refinancing risk (score 3/10).

Maturity Schedule

Year 1 $781M Year 2 $1.5B Year 3 $2.5B Year 4 $442M Year 5 $3.1B Beyond 5 $0
Period Amount Due % of Total
Year 1 (0-12 months) $781M 9.4%
Year 2 (12-24 months) $1.5B 18.3%
Year 3 (24-36 months) $2.5B 30.2%
Year 4 (36-48 months) $442M 5.3%
Year 5 (48-60 months) $3.1B 36.9%
Beyond 5 Years N/A N/A
Total Scheduled Maturities $8.3B 100.0%

Key Metrics

Total Long-Term Debt
$19.1B
Near-Term (12mo)
$781M
Interest Coverage
N/A
Debt/Equity
1.34
Cash Coverage
4.18x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 9.4% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 1.34 25%
Cash Coverage of Near-Term Debt 4.18x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-12. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.